Stonepine Capital Management, LLC
Bend, OR · CIK 1440771 · 13F filing filed 2024-08-21
SEC-registered investment adviser since 2026 · limited liability company
- Assets managed$181.0m
- Staff4 · 3 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $181.0m gross assets
- Websitestonepinecap.com
- Form ADV · 2026-06-26SEC adviser record
- Legal entitySTONEPINE CAPITAL MANAGEMENT, LLC (US)
- Kindhedge funds, futures
- Others nearbyBend, OR, Sausalito, CA
As an employer
- Offices in1 country
- Private fundshedge 2
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| Bend, OR (main office)United States | about 1 |
| Sausalito, CA2 officesUnited States | 2 |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Holdings, Q2 2024
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| ADMA BIOLOGICS INC ADMA | $20.9m19.07% | Reduced -1.6m |
| ALIMERA SCIENCES INC ALIM | $19.5m17.81% | Reduced -539.3k |
| EVOLUS INC EOLS | $18.0m16.41% | Reduced -1.0m |
| GALAPAGOS NV LKFT | $12.0m10.97% | Added +91.4k |
| REVANCE THERAPEUTICS INC RVNC | $7.2m6.57% | Added +823.7k |
| XOMA ROYALTY CORPORATION XOMA | $5.9m5.41% | Reduced -3.6k |
| ANIKA THERAPEUTICS INC ANIK | $4.2m3.82% | Added +104.4k |
| TELA BIO INC TELA | $2.9m2.68% | Reduced -62.6k |
| RIGEL PHARMACEUTICALS INC RIGL | $2.5m2.29% | New |
| OPTINOSE INC COM | $2.4m2.23% | New |
| ACLARIS THERAPEUTICS INC ACRS | $2.1m1.93% | New |
| SCPHARMACEUTICALS INC SCPH | $1.8m1.67% | Reduced -25.1k |
| AURINIA PHARMACEUTICALS INC AUPH | $1.7m1.56% | New |
| MILESTONE PHARMACEUTICALS IN MIST | $1.6m1.49% | Reduced -223.1k |
| AYTU BIOPHARMA INC AYTU | $1.4m1.26% | Unchanged |
| KIORA PHARMACEUTICALS INC EYEG | $840.0k0.77% | New |
| ADICET BIO INC COM | $737.4k0.67% | Added +467.9k |
| SURROZEN INC SRZN | $723.6k0.66% | New |
| EXAGEN INC XGN | $652.8k0.60% | Reduced -25.9k |
| KEZAR LIFE SCIENCES INC COM | $630.3k0.58% | New |
| APREA THERAPEUTICS INC APRE | $558.3k0.51% | New |
| 2SEVENTY BIO INC TSVT | $385.0k0.35% | New |
| ETON PHARMACEUTICALS INC ETON | $361.9k0.33% | New |
| IRONWOOD PHARMACEUTICALS INC IRWD | $313.0k0.29% | New |
| ACADIA PHARMACEUTICALS INC ACAD | $81.2k0.07% | New |
Sold out since Q1 2024
| Security | Value then |
|---|---|
| NEKTAR THERAPEUTICS | $3.3m3.5m shares |
| CALCIMEDICA INC | $2.2m522.6k shares |
| RIGEL PHARMACEUTICALS INC | $1.5m1.0m shares |
| XERIS BIOPHARMA HOLDINGS INC XERS | $1.3m598.1k shares |
| REZOLUTE INC RZLT | $309.8k121.5k shares |
| IO BIOTECH INC IOBTQ | $270.2k156.2k shares |
| SCYNEXIS INC | $140.6k95.6k shares |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| QUOIN PHARMACEUTICALS LTD QNRX · 13G · filed 2026-05-15 | 10.0% |
| AEON BIOPHARMA INC AEON · 13G · filed 2026-07-21 | 9.9%≈ $3.9m |
| AZITRA INC 13G · filed 2026-06-22 | 9.9% |
| ELOXX PHARMACEUTICALS INC ELOX · 13G · filed 2026-06-16 | 9.9%≈ $5.6m |
| SINTX TECHNOLOGIES INC SINT · 13G · filed 2026-06-09 | 9.9%≈ $1.2m |
| CNS PHARMACEUTICALS INC CNSP · 13G · filed 2026-05-15 | 9.9%≈ $760.7k |
| CELLECTAR BIOSCIENCES INC CLRB · 13G · filed 2026-05-11 | 9.9%≈ $2.4m |
| CURIS INC 13G · filed 2026-03-27 | 9.9%≈ $2.1m |
| IN8BIO INC INAB · 13G · filed 2025-12-22 | 9.9%≈ $1.4m |
| AYTU BIOPHARMA INC AYTU · 13G · filed 2025-08-13 | 9.9%≈ $1.9m |
| OPTINOSE INC OPTN · 13G · filed 2025-05-14 | 7.8% |
| FEMASYS INC FEMY · 13G · filed 2026-08-31 | 7.2%≈ $2.6m |
| EDESA BIOTECH INC EDSA · 13G · filed 2026-08-26 | 6.9%≈ $5.9m |
| CALCIMEDICA INC 13G · filed 2026-08-25 | 6.0%≈ $2.2m |
| TELA BIO INC TELA · 13G · filed 2025-02-13 | 6.0%≈ $1.8m |
| PASITHEA THERAPEUTICS CORP KTTA · 13G · filed 2026-06-23 | 5.8%≈ $1.0m |